| Website | intellikine.com |
| Category | BioTech |
| Phone | 858.768.6500 |
| Employees | |
| Description | Oncology Pharmaceuticals |
| Series B, 7/09 Novartis Ventures US Venture Partners Biogen Idec Abingworth CMEA Capital Sofinnova Ventures | $51M |
Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway.
Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.
